Document is current
Any future updates will be listed below
-
Authors
Cordas dos Santos, David M.
Tix, Tobias
Shouval, Roni
Gafter-Gvili, Anat https://orcid.org/0000-0003-1666-5114
Alberge, Jean-Baptiste
Cliff, Edward R. Scheffer https://orcid.org/0000-0001-5977-907X
Theurich, Sebastian https://orcid.org/0000-0001-5706-8258
von Bergwelt-Baildon, Michael
Ghobrial, Irene M. https://orcid.org/0000-0001-7361-3092
Subklewe, Marion
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
Rejeski, Kai https://orcid.org/0000-0003-3905-0251
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (Walter-Benjamin Fellowship)
Deutsche Forschungsgemeinschaft (SFB-TRR 388/1 2021 - 452881907)
Deutsche Forschungsgemeinschaft (SFB-TRR 388/1 2021 - 452881907)
- License Information
-
More Information
Article History
Received: 28 January 2024
Accepted: 22 May 2024
First Online: 8 July 2024
Competing interests
: A.G.-G. received honoraria from/had a consultancy with Pfizer, Bayer, Novartis, Neopharm, Roche, Medison, Sanofi, AstraZeneca and Boehringer-Ingelheim. S.T. received honoraria from/had a consultancy with Amgen, BMS/Celgene, GSK, Janssen, Pfizer, Sanofi, Takeda, Stemline and Kyowa Kirin. M.V.B.-B. had a consultancy and received research funding and honoraria from MSD Sharp & Dohme, Novartis, Roche, Kite/Gilead, Bristol-Myers Squibb, Astellas, Mologen and Miltenyi. I.M.G. received honoraria from Celgene, Bristol-Myers-Squibb, Takeda, Amgen, Janssen and Vor Biopharma, and had a consultancy/advisory role with Bristol-Myers-Squibb, Novartis, Amgen, Takeda, Celgene, Cellectar, Sanofi, Janssen, Pfizer, Menarini Silicon Biosystems, Oncopeptides, The Binding Site, GSK, Abbvie, Adaptive and 10X Genomics. M.S. receives industry research support from Amgen, BMS/Celgene, Gilead, Janssen, Miltenyi Biotec, Novartis, Roche, Seattle Genetics and Takeda, and serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Pfizer and Takeda. She serves on the speakers’ bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche and Takeda. M.-A.P. reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG and Vor Biopharma. He serves on data and safety monitoring boards for Cidara Therapeutics, Medigene and Sellas Life Sciences, and on the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros and OrcaBio and has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics and Novartis. K.R. has received research funding, consultancy, honoraria and travel support from Kite/Gilead; honoraria from Novartis; consultancy and honoraria from BMS/Celgene; and travel support from Pierre-Fabre. The other authors declare no competing interests. None of the mentioned conflicts of interest was related to financing of this study.
